VC  BVF Partners

https://bvflp.com/





     Office Locations:

44 Montgomery St
40th Floor
San Francisco, CA 94104
Phone: 415-525-8800

 

Stages:

  • Early


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    BVF Partners L.P. is a San Francisco-based private investment partnership specializing in fundamentally-driven public biotechnology investments. Since its inception in 1993, BVF has strived to build concentrated, long-term investments in small-cap biotechnology companies while performing rigorous diligence and on-going monitoring of its investments.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or Silicon Valley Database subscription.
    Kanishka Pothula Managing Director
    Matthew Perry President
    Spike Loy Managing Director

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      10/23/2024


      Alpha-9 Oncology


      MA


      $175,000,000


      Series C


      09/09/2024


      Bambusa Therapeutics


      MA


      $5,000,000


      Seed


      08/20/2024


      Ambrosia Biosciences


      CO


      $16,000,000


      Series A


      07/23/2024


      Third Arc Bio


      MA


      $165,000,000


      Series A


      05/21/2024


      AltruBio


      CA


      $225,000,000


      Series B


      04/03/2024


      Diagonal Therapeutics


      MA


      $128,000,000


      Series A


     

    Portfolio companies include:

     

    Recent News: